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OBJECTIVES We sought to evaluate the effects of carvedilol on mortality and morbidity in dialysis patients
with dilated cardiomyopathy.
BACKGROUND Several lines of evidence support the concept that therapy with beta-blocking agents reduces
morbidity and mortality in patients with congestive heart failure (HF), but the demonstration
of such a survival benefit in dialysis patients with dilated cardiomyopathy is still lacking.
METHODS A total of 114 dialysis patients with dilated cardiomyopathy were randomized to receive either
carvedilol or placebo in addition to standard therapy. A first analysis was performed at one
year and was followed by an additional follow-up period of 12 months.
RESULTS Two-year echocardiographic data revealed a significant attenuation of pathologic remodeling,
with smaller cavity diameters and higher ejection fractions in the active treatment group than
in the placebo group. At two years, 51.7% of the patients died in the carvedilol group,
compared with 73.2% in the placebo group (p  0.01). Furthermore, there were significantly
fewer cardiovascular deaths (29.3%) and hospital admissions (34.5%) among patients
receiving carvedilol than among those receiving a placebo (67.9% and 58.9%, respectively; p
0.00001). The exploratory analyses revealed that fatal myocardial infarctions, fatal strokes,
and hospital admissions for worsening HF were lower in the carvedilol group than in the
placebo group. A reduction in sudden deaths and pump-failure deaths was also observed,
though it did not reach statistical significance.
CONCLUSIONS Carvedilol reduced morbidity and mortality in dialysis patients with dilated cardiomyopathy.
These data suggest the use of carvedilol in all dialysis patients with chronic HF. (J Am Coll
Cardiol 2003;41:1438–44) © 2003 by the American College of Cardiology Foundation
The demonstration that therapy with beta-adrenergic
blocking agents improves survival in congestive heart failure
(CHF) (1–3) has recently prompted us to evaluate the
effects of carvedilol, a third-generation beta-blocking drug
endowed with vasodilator properties, in dialysis patients
affected with dilated cardiomyopathy. Despite the routine
pharmacologic therapy and the optimization of the dialysis
regimen, such particular subset of patients exhibits an
inexorable disease progression, with a very high mortality
and morbidity (4–6).
After our initial investigation, which showed improved
clinical status and left ventricular (LV) function in dialysis
patients with dilated cardiomyopathy after 12 months of
carvedilol therapy (7), we followed up the same patient
population for an additional 12-month period. Not only
clinical status and LV structure and function were evaluated,
but also the mortality rate. The results of the current study
provide the first demonstration that carvedilol can prolong
survival in dialysis patients with dilated cardiomyopathy.
METHODS
Patients. Recruitment criteria were previously described
(7). Briefly, from February 1996 to December 1998, we
recruited 132 patients (89 men, 43 women; mean age, 55.1
 7.6 years) with uremia on periodic hemodialysis treat-
ment and dilated cardiomyopathy. All patients were symp-
tomatic for heart failure (HF) (New York Heart Association
[NYHA] functional class II to III) for at least one year, with
an left ventricular ejection fraction (LVEF) 0.35 at echocar-
diography. To be included in the study, patients had to be
clinically stable with no change in their usual medications in
the last two weeks and should not have required intravenous
inotropic drug therapy or experienced weight changes for at
least 48 h before the enrollment (2.5 kg compared with
the “dry weight”). Exclusion criteria included: current
NYHA functional class IV; heart rate 50 beats/min; sick
sinus syndrome; first degree atrioventricular block with a
PQ interval 0.24 s, second- or third-degree heart block
(unless controlled by a pacemaker); documented episodes of
sustained ventricular tachycardia (30 s, 120 beats/min);
systolic blood pressure (BP) 90 mm Hg; stroke, acute
myocardial infarction (MI), unstable angina, coronary an-
gioplasty, or aortocoronary bypass surgery in the three
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previous months; uncorrected valvular heart disease; active
myocarditis; obstructive and restrictive cardiomyopathy;
current treatment with verapamil, alpha/beta adrenergic
agonists or antagonists; chronic obstructive airways disease;
hepatic disease (serum transaminase3 times normal); drug
or alcohol abuse; or any other life-threatening non-cardiac
disease.
All patients were receiving digitalis; 128 patients (96.9%)
were also receiving angiotensin-converting enzyme (ACE)
inhibitors; four patients (3.1%) who were intolerant of the
ACE inhibitors received angiotensin II receptor antago-
nists; 32 (25%) patients were taking nitrates.
All patients were dialyzed four times a week, for a mean
time of 210  30 min, with a middle quote blood of 260 
20 ml/min, using a cuprophan hollow-fiber hemodialyzer by
1.3 to 1.8 m2 of surface and 7.5  of thickness. A
personalized bath of dialysis was used, with variable con-
centration of potassium between 2 and 3.5 mEq/l. The
concentration of sodium was variable between 144 and 150
mEq/l in relation to the BP. Monitors were used for
computerized checking of ultrafiltration and real time mon-
itoring of the loss of the weight, so as to have an exact and
constant control of the weight reduction per hour. Further-
more, heart rate and BP were checked. The “dry weight” of
all patients was stable for at least one month.
Design and study treatment. All inclusion criteria, the
“run-in” phase, and the titration period are described in
detail elsewhere (7). Upon completion of a one-year obser-
vation period, codes were broken, and the clinical and
echocardiographic data were collected and reported in a
previous publication (7). Subsequently, all patients were
followed up for an additional 12 months. The current trial
was, therefore, designed as a prospective, open-label,
placebo-controlled, randomized clinical study. As previously
described (7), at the end of the up-titration phase, the
therapy with carvedilol or placebo was maintained for 24
months (maintenance phase), during which time carvedilol
was administered at the maximum dose of 25 mg twice a day
or to the highest dose tolerated. Concomitant therapy with
digitalis, ACE inhibitors, angiotensin II receptor antago-
nists, and nitrates was maintained, although the dosage was
adjusted according to the clinical conditions of the patient
or to the appearance of side effects possibly related to these
drugs.
End points and assessment. The patients were checked
with daily medical examinations during titration and every
other day during the maintenance phase in concomitance
with dialysis.
The primary end points were the same as reported in the
previous one-year investigation and included changes in LV
end-diastolic volume (LVEDV), in LV end-systolic volume
(LVESV), in ejection fraction, and in clinical status 24
months after randomization. Secondary end points were
all-cause mortality, all-cause hospital admission, cardiovas-
cular mortality, acute non-fatal MI, combined end point
(cardiovascular mortality plus acute non-fatal MI), cardio-
vascular hospital admission, and permanent premature
treatment withdrawals.
In the exploratory analyses regarding the cause of death,
critical events were classified according to strict definitions.
“Acute MI” was defined as a cardiac event requiring
admission to the hospital, with development of new elec-
trocardiographic changes and cardiac enzyme (troponin I)
level increases. “Sudden death” was defined as death occur-
ring within 1 h, without previous worsening of symptoms of
HF. We also took unexpected deaths occurring during sleep
to be “sudden” when patients were found deceased by family
members in the morning when sharing the same room. We
classified other unwitnessed deaths as “unknown.” We
classified as “pump failure death” that which occurred as a
consequence of progressive deterioration of HF, acute
pulmonary edema, or cardiogenic shock. Fatal MI and fatal
stroke were classified as “other cardiovascular deaths.” If
cardiovascular events were excluded as the cause of a death,
we recorded it as “non-cardiovascular death.” Death was
classified as being due to an unknown cause when there was
insufficient evidence to confirm a cardiovascular or non-
cardiovascular cause.
We recorded a “permanent treatment withdrawal” when-
ever intolerance to study medication occurred, despite in-
creases in baseline therapy, if study-drug dose was decreased
or temporarily withdrawn, if patients experienced intoler-
ance to first dose, and for all other circumstances in which
study drug was permanently stopped.
The patients were informed in detail of the formalities
and finality of the study. All patients provided written
informed consent to participate. The institutional commit-
tee on human research approved the study protocol.
Among the 132 patients eligible for the inclusion in the
trial, 18 were excluded during the run-in phase. Thus, 114
patients, whose clinical characteristics are reported else-
where (7), started the maintenance phase.
Statistics. The analyses of primary and secondary end
points included all the patients, according to the intention-
to-treat principle. Descriptive statistical procedures were
used to assess the distribution of each variable. The analyses
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BP  blood pressure
CHF  congestive heart failure
CI  confidence interval
HF  heart failure
HR  hazard ratio
Kur  kurtosis
LV  left ventricle/ventricular
LVEDV  left ventricular end-diastolic volume
LVEF  left ventricular ejection fraction
LVESV  left ventricular end-systolic volume
MI  myocardial infarction
NYHA  New York Heart Association
Ske  skewness
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were performed by SPSS for Windows release 11.0 (Chi-
cago, Illinois). Data are presented as mean  SD.
For continuous variables, between-group comparisons
were performed using the two-way analysis of variance
(ANOVA), with treatment as one factor and time as the
other factor. Comparisons to determine the significance of
changes within the same group over time and between
groups at each time point were performed with the
Newman-Keul post-hoc test, using ANOVA models for
repeated measures. Chi-square test was used for categorical
variables like NYHA class.
Samples were tested for normal distribution by Box-
Bartlett homogeneity test and by skewness (Ske) and kur-
tosis (Kur) analyses. In particular, Ske measured the asym-
metry of the distribution, while Kur showed the extent to
which observations clustered around a central point. By such
analyses, continuous variables showed a normal distribution:
heart rate (Ske, 0.3; Kur, 0.4), systolic BP (Ske, 0.4; Kur,
0.3), diastolic BP (Ske, 0.4; Kur, 0.3), LVEDV (Ske, 0.2;
Kur, 0.3), LVESV (Ske, 0.3; Kur, 0.4), LVEF (Ske, 0.3;
Kur, 0.2).
Hazard ratios (HR) and 95% confidence intervals (CI) for
cardiac events were assessed by multivariable Cox propor-
tional hazards regression models, in order to explore the
effects of baseline variables on the estimated effects of
carvedilol. Kaplan-Meier survival curves on cardiac events
were calculated, and differences between treatment groups
were assessed by use of the log-rank test (time to event).
Differences were significant at p  0.05.
RESULTS
Dropout patients. Of 132 patients entering the run-in
phase, 18 (13.6%) were excluded due to side effects: hypo-
tension (n  3), dizziness (n  1), bronchospasm (n  5),
bradycardia (n  4), worsening HF (n  4), and protocol
violation (n  1). Of 114 patients starting the titration
phase, no one was excluded. Of 114 patients entering the
maintenance phase, 11 (9.6%) dropped out of the study.
Four patients in the carvedilol group dropped out: one for
the appearance of hypotension, one for bradycardia, one for
second-degree heart block, and one because of acute MI.
Seven patients in the placebo group dropped out: three for
worsening HF, two because of protocol violation, one
because of acute non-fatal MI, and one because of refractory
hyperkalemia.
Echocardiographic parameters and clinical status as-
sessed as NYHA. The echocardiographic data and clinical
status assessment (Tables 1 and 2) revealed that structural
and functional benefits obtained by one-year carvedilol
therapy were maintained also at year 2, insofar as LV cavity
diameters and ejection fraction were similar in the active
treatment group at both time points.
Mortality. Mortality was not significantly different be-
tween the two groups at one year (0/58 in carvedilol group
vs. 3/56 in placebo group, p  NS). At two years in the
carvedilol group, 30 patients (51.7%) died, compared with
41 (73.2%) in the placebo group (p  0.01). There were
significantly fewer all-cardiovascular deaths (29.3% vs.
67.9%, p  0.00001) among patients receiving carvedilol
than among those receiving placebo. In particular, the main
reduction was observed in the number of other cardiovas-
cular deaths (22.5% vs. 42.9%, p  0.01). Also, the number
of sudden deaths and pump failure deaths was reduced by
carvedilol treatment, even if non-significantly differing be-
tween the two groups (Table 3).
By Cox proportional-hazards regression analysis, the use
Table 1. HR, Blood Pressure, and Echocardiographic Parameters in the Carvedilol and Placebo Groups
Carvedilol Placebo
Basal 1 Month 6 Months 12 Months 24 Months Basal 1 Month 6 Months 12 Months 24 Months
HR (beats/min) 93  11 69  7*† 69  7*† 69  7*† 66  5*† 93  12 92  12 91  12 92  12 94  10
SBP (mm Hg) 134  8 124  7*† 123  7*†‡ 123  8*†‡ 120  8*†‡ 135  9 134  9 133  10 133  11 135  10
DBP (mm Hg) 75  6 68  6*† 67  6*†‡ 67  6*†‡ 70  4*†‡ 75  6 74  6 75  6 73  6 76  9
LVEDV (ml/m2) 100  9 99  8 94  8*†‡ 94  4*†‡ 94  5*†‡ 97  8 97  8 99  6 98  6 100  5
LVESV (ml/m2) 74  8 72  8 62  8*†‡ 62  8*†‡ 64  6*†‡ 72  9 72  8 72  8 72  8 74  3
LVEF (%) 26  8 27  7 35  11*†‡ 36  11*†‡ 37  10*†‡ 26  8 26  8 27  8 26  8 24  10
*p  0.05 vs. basal; †p  0.05 vs. placebo; ‡p  0.05 vs. control at one month.
DBP  diastolic blood pressure; HR  heart rate; LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV  left ventricular
end-systolic volume; SBP  systolic blood pressure.
Table 2. Assessment of NYHA Class Over the Treatment Period
Carvedilol (54 Patients) Placebo (49 Patients)
Basal 6 Months 12 Months 24 Months Basal 6 Months 12 Months 24 Months
Class I 0 (0%) 3 (5.6%)* 4 (7.4%)* 2 (8.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Class II 18 (33.3%) 34 (63%)* 35 (64.8%)* 16 (66.7%) 22 (44.9%) 19 (38.8%) 19 (38.8%) 3 (33.4%)
Class III 36 (66.7%) 17 (31.4%)* 15 (27.8%)* 6 (25%) 27 (55.1%) 28 (57.1%) 27 (55.1%) 4 (44.4%)
Class IV 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (4.1%) 3 (6.1%) 2 (22.2%)
*p  0.05 vs. basal.
NYHA  New York Heart Association
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of carvedilol appeared to be a strong independent predictor
of both all-cause mortality (HR, 0.51; 95% CI, 0.32 to 0.82;
p  0.01) and cardiovascular mortality (HR, 0.32; 95% CI,
0.18 to 0.57; p  0.0001).
The cumulative two-year mean survival time was 20.37
months in the carvedilol group and 18.33 months in the
placebo group (log-rank, 8.58; p  0.005) (Fig. 1). Of
interest, 12-month mortality rate was 0% in the carvedilol
group versus 5.2% in the placebo group (p  NS), but it
increased, respectively, to 51.7% and 73.2% (p  0.01) at
two-year follow-up. In addition, patients receiving carve-
dilol showed increased two-year survival time free of car-
diovascular deaths compared with placebo patients (21.7 vs.
18.1 months, respectively; log-rank, 17.14; p  0.00001)
(Fig. 2).
Hospital admissions. Significantly fewer patients receiving
carvedilol were admitted to the hospital for all causes (20
patients, 34.5%) than placebo patients (33 patients, 58.9%)
(p  0.005). In particular, the difference in hospital admis-
sion for worsening HF was 43.3% (8 patients, 13.8%, in
carvedilol group vs. 32 patients, 57.1%, in placebo group;
p  0.00001). Conversely, the number of hospital admis-
sions for acute non-fatal MI, combined end point, or pump
failure did not significantly differ between the two groups.
Table 3. Secondary End Points and Exploratory Analyses
Placebo
(n  56)
Carvedilol
(n  58)
Hazard Ratio
(95% CI)
p
Value
Secondary End Points
All-cause mortality 41 (73.2%) 30 (51.7%) 0.51 (0.32–0.82)  0.01
All-cause hospital admission 33 (58.9%) 20 (34.5%) 0.44 (0.25–0.77)  0.005
All cardiovascular deaths 38 (67.9%) 17 (29.3%) 0.32 (0.18–0.57)  0.0001
Non-fatal myocardial infarction 1 (1.8%) 0 (0%) 0.81 (0.61–1.34) 0.31
Combined end point 39 (69.6%) 17 (29.3%) 0.76 (0.47–1.22) 0.22
Permanent treatment withdrawals 15 (26.8%) 17 (29.3%) 1.12 (0.84–1.24) 0.68
Exploratory Analyses
Sudden deaths 6 (10.6%) 2 (3.4%) 0.76 (0.52–1.13) 0.12
Pump-failure deaths 8 (14.4%) 2 (3.4%) 0.23 (0.05–1.23) 0.056
Other cardiovascular deaths 24 (42.9%) 13 (22.5%) 1.13 (0.82–1.2) 0.01
Non-cardiovascular deaths 2 (3.6%) 12 (20.7%) 0.76 (0.44–1.33) 0.02
Unknown cause of death 1 (1.7%) 1 (1.7%) 0.95 (0.55–1.3) 0.98
Hospital admission for worsening heart failure 32 (57.1%) 8 (13.8%) 0.19 (0.09–0.41)  0.00001
CI  confidence interval.
Figure 1. Kaplan-Meyer curves for all-cause mortality during 24-month follow-up cumulative survival rate according to use of carvedilol. Solid lines 
carvedilol group; dashed lines  placebo group.
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The number of permanent treatment withdrawals was
similar in the two groups.
By use of Cox regression analysis, treatment with carve-
dilol was independently associated with both reduced all-
cause hospital admission (HR, 0.44; 95% CI, 0.25 to 0.77;
p  0.005) and hospital admission for worsening HF (HR,
0.19; 95% CI, 0.09 to 0.41; p  0.00001).
By Kaplan-Meier analyses, patients receiving carvedilol
showed increased two-year mean survival time free of
hospital admissions compared with patients receiving pla-
cebo (20.9 vs. 16.2 months, respectively; log-rank, 8.8; p 
0.005) (Fig. 2). Of note, two-year mean survival time free of
hospital admissions for worsening HF was 21.26 months in
the carvedilol group and 13.98 months in the placebo group
(log-rank, 22.7; p  0.00001).
DISCUSSION
Several lines of experimental evidence support the concept
that therapy with beta-blockers reduces morbidity and
mortality in CHF, but the demonstration of such a survival
benefit in specific subgroups of patients is still lacking. In
this regard, dialysis patients with CHF have been reported
to have a higher mortality rate than non-uremic subjects
(8–10). In a recently published study (7), we have demon-
strated that carvedilol therapy attenuates the echocardio-
graphic signs of pathologic remodeling, insofar as LV cavity
diameters were reduced and ejection fraction increased after
one year of carvedilol therapy, compared with baseline
evaluation and placebo-treated subjects.
Herein, we report two-year data from the same patient
population. In addition to the maintenance of LV structural
and functional benefits, carvedilol therapy significantly re-
duced mortality compared with standard therapy. Specifi-
cally, all-cause mortality, all-cause hospital admission, all-
cardiovascular mortality, fatal MIs and stroke, and
cardiovascular hospital admission were all significantly im-
proved in the carvedilol group compared with the placebo
arm.
CHF in dialysis patients. Cardiovascular mortality ranks
as the principal cause of death in dialysis patients (1–3). In
the current study, we not only document beneficial effects of
carvedilol on survival and LV function, but we also report
novel data about mortality in dialysis patients with dilated
cardiomyopathy. Specifically, we observed a dramatic and
unexpected rise of mortality rate in our placebo arm from
5.2% to 73.2%, and in the carvedilol group from 0% to
51.7%, in the first and second years of observation, respec-
tively. In this regard, few studies have described survival
curves in dialysis patients with CHF. The landmark study
by Harnett et al. (9) identified the primary determinants for
the development of CHF in a patient population of 432
dialysis patients followed up for a mean of 41 months.
Independent predictors were systolic dysfunction, older age,
diabetes mellitus, and ischemic heart disease, while poten-
tially reversible abnormalities included anemia, hyperten-
sion, and hypoalbuminemia. Compared with the observa-
tions of Harnett et al. (9), which reported a median survival
in the CHF group of 36 months, the current study displays
a considerably higher mortality rate. This discrepancy may
be explained by the worse clinical status and pathologic
remodeling of our patients at the study entry. Specifically,
we recruited only patients with NYHA functional classes II
and III, and with an ejection fraction lower than 0.35 at
echocardiography. As a consequence, almost two-thirds of
our patient population was in NYHA class III at the study
entry, with an average ejection fraction of 0.26 and an
indexed end-diastolic volume of 100 ml/m2, compared with
a mean fractional shortening and LV end-diastolic diame-
ters of 0.30 and 53 mm in Harnett’s study, respectively. In
other words, all our patients displayed the typical features of
Figure 2. Kaplan-Meyer curves for cardiovascular death (left) and for all-cause hospital admission (right) during 24-month follow-up cumulative survival
rate according to use of carvedilol. Solid lines  carvedilol group; dashed lines  placebo group.
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dilated cardiomyopathy, whereas, in the Canadian study,
patients with minor degrees of HF were also included in the
analysis.
The causes of excess mortality in dialysis patients with
CHF are not entirely elucidated. They include volume
overload with consequent hypertension, anemia, impaired
calcium-phosphate handling, specific uremic toxin accumu-
lation (advanced glication end-products, asymmetric di-
methyl arginine, and homocysteine), chronic inflammatory
processes, electrolytic abnormalities with attendant electrical
heterogeneity and arrhythmias, and the calcification of
coronary arteries, leading to ischemic heart disease refrac-
tory to medical treatment and interventional procedures
(11,12).
Carvedilol effects in dialysis patients with CHF. Pre-
vious studies from our group have recently documented the
efficacy and safety of carvedilol in both uremic (7) and
non-uremic (13) CHF patients. In particular, in chronic
hemodialyzed patients that usually show a peculiar neuro-
humoral status (14–16), these benefits are justified by the
adequate management of systemic hypertension, arrhyth-
mias, and “silent” angina (17–19). Moreover, among other
beta-blocking agents, in such patients carvedilol is endowed
with favorable kinetic characteristics, in view of its prevalent
hepatic metabolism that does not require dose adjustment in
case of impaired renal function (20).
The echocardiographic data show that anti-remodeling
actions exhibited by carvedilol at one year were maintained
after 12 months of therapy, with no evident signs of disease
progression as assessed by LV cavity diameters, ejection
fraction, and NYHA class. These findings were associated
with a 23% absolute reduction of mortality rates in the
carvedilol group, whose use resulted as a strong and inde-
pendent predictor of all-cause and cardiovascular mortality.
The exploratory analyses revealed that both “other car-
diovascular deaths” and “hospital admissions for worsening
HF” were lower in the carvedilol group than in the placebo
group. Furthermore, a reduction in sudden deaths and
pump-failure deaths was also observed, even if it did not
meet statistical significance.
Our findings emphasize carvedilol efficacy in determining
a significant reduction both of fatal MIs and of fatal strokes,
which represent the main causes of cardiovascular mortality
in uremic patients (5). These benefits may be related to the
well-known anti-ischemic properties of carvedilol: the abil-
ity to reduce systemic BP, heart rate, and myocardial oxygen
demand; to decrease the risk of plaque rupture; and to
reduce the frequency and the complexity of ventricular
arrhythmias (13). In addition, carvedilol exerts antioxidant
effects that may further protect the heart from ischemia or
reperfusion damage (21), independent of its actions as an
adrenoceptor blocker.
As for the effects of carvedilol treatment on LV pump
function, data from the first year of the study documented
improvement in remodeling and systolic parameters after six
months of carvedilol therapy. However, most of the deaths
in both groups occurred in the second year of the study,
despite these effects on pump function. Intermediate time
points of analysis between 12 and 24 months would have
detected significant worsening of clinical and echocardio-
graphic parameters before the fatal episodes of pump failure.
On the other hand, anti-apoptotic, anti-inflammatory, and
antiproliferative effects of carvedilol have just begun to be
elucidated and might be at play, particularly in dialysis
patients with CHF, in whom the cytokine system is
maximally activated (22,23).
It must be stressed that the limited sample size does not
allow us to draw definite conclusions, insofar as sudden
deaths were lower in the active treatment group (two
deaths) than in the placebo group (six fatal events), making
it possible that in a larger patient population significant
differences would have been detected. Future studies are
needed to clarify this issue.
Although the cost evaluation is not one of the aims of our
study, a final comment regarding the significant reduction
of all-cause hospital admission and admission for worsening
HF observed in our population may be of interest. Consid-
ering that during the last 10 years the annual number of
hospitalizations has increased from approximately 1.7 to
nearly 2.6 million for HF as a primary or secondary
diagnosis, these data suggest that carvedilol therapy may
lead to a remarkable reduction of health care costs.
Study limitations. The main limitation of this study is the
small sample of the study group. However, it should be
underlined that our population represents a very selected
group of dialysis patients with dilated cardiomyopathy in
advanced NYHA class, exhibiting, despite routine pharma-
cologic therapy and optimization of the dialysis regimen, a
very high mortality and morbidity. Furthermore, to the best
of our knowledge, no previous reports have analyzed carve-
dilol effects on mortality rate in such a particular subset of
patients.
The lack of a double-blind design might be viewed as a
potential limitation of the study. Maybe it influenced several
measurements, especially NYHA class. However, it appears
unlikely that this exerted a significant impact on the
mortality curves of the study groups.
Conclusions. In summary, the data of the current investi-
gation demonstrate that dilated cardiomyopathy in dialysis
patients is characterized by a very poor prognosis, with a
two-year mortality rate of 71%, and that carvedilol therapy
prolongs survival in addition to providing a significant
improvement in LV function and clinical status. Such
beneficial effects were obtained independent of the cause of
HF and of the patients’ clinical status at the study entry.
In conclusion, even admitting the intrinsic limitations of
our study (open-label, unblinded trial), the main finding is
to have shown the feasibility of carvedilol therapy in dialysis
patients with dilated cardiomyopathy and its efficacy in
determining a significant reduction of morbidity and mor-
tality. Further double-blinded, placebo-controlled trials may
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be necessary to confirm such beneficial effects of carvedilol
in this subset of patients with such a poor prognosis.
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